Environmental Endocrine Disruption of Energy Metabolism and Cardiovascular Risk

Macrovascular Complications in Diabetes (L Perreault, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Macrovascular Complications in Diabetes

Abstract

Rates of metabolic diseases have increased at an astounding rate in recent decades. Even though poor diet and physical inactivity are central drivers, these lifestyle changes alone fail to fully account for the magnitude and rapidity of the epidemic. Thus, attention has turned to identifying novel risk factors, including the contribution of environmental endocrine disrupting chemicals. Epidemiologic and preclinical data support a role for various contaminants in the pathogenesis of diabetes. In addition to the vascular risk associated with dysglycemia, emerging evidence implicates multiple pollutants in the pathogenesis of atherosclerosis and cardiovascular disease. Reviewed herein are studies linking endocrine disruptors to these key diseases that drive significant individual and societal morbidity and mortality. Identifying chemicals associated with metabolic and cardiovascular disease as well as their mechanisms of action is critical for developing novel treatment strategies and public policy to mitigate the impact of these diseases on human health.

Keywords

Atherosclerosis Cardiovascular disease Endocrine disruptors Diabetes Pollution Environment Energy metabolism Cardiovascular risk 

Notes

Acknowledgments

Due to reference constraints, the authors were unable to include all the important work performed in the field of endocrine disruption of metabolism and cardiovascular disease. The current manuscript was meant to emphasize important aspects of environmental disruption of energy homeostasis and cardiovascular risk; any omissions were not meant to exclude important work contributing to the hypothesis that environmental contaminants play an important pathogenic role in the global epidemic of metabolic and cardiovascular disease. This work was supported by grants from the National Institutes of Health (K08-ES019176, R21-ES021354, and the Diabetes Research and Training Center [P60-DK020595]).

Compliance with Ethics Guidelines

Conflict of Interest

Andrew G. Kirkley declares that he has no conflict of interest. Robert M. Sargis has received honoraria from the Korean Diabetes Association.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2011.Google Scholar
  2. 2.
    ADA. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.Google Scholar
  3. 3.
    Imperatore G, Boyle JP, Thompson TJ, Case D. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050. Diabetes Care. 2012;35:2515–20.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Gregg EW, Boyle JP, Thompson TJ, Barker LE. Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030. Popul Health Metrics. 2013;11.Google Scholar
  5. 5.
    International Diabetes Federation (IDF). Diabetes atlas. 6th edition. 2013.Google Scholar
  6. 6.
    Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013:653789.Google Scholar
  7. 7.
    Cherian B, Meka N, Katragadda S, Arora R. Therapeutic implications of diabetes in cardiovascular disease. Am J Ther. 2009;16:e51–9.Google Scholar
  8. 8.
    Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on cardiovascular complications of type 1 diabetes mellitus. Circulation. 2005;111:3489–93.PubMedGoogle Scholar
  9. 9.
    Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.PubMedGoogle Scholar
  10. 10.
    Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123:556. e551–9.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Hill JO. Environmental contributions to the obesity epidemic. Science. 1998;280:1371–4.PubMedGoogle Scholar
  12. 12.
    Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002;8:185–92.PubMedGoogle Scholar
  13. 13.•
    Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environ Health Perspect. 2012;120:779–89. An important overview of the work performed by the National Toxicology Program in reviewing the evidence linking various pollutants with the development of metabolic disease.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30:293–342.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Lee DH, Lee IK, Porta M, Steffes M, Jacobs Jr DR. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetologia. 2007;50:1841–51.PubMedGoogle Scholar
  16. 16.
    Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep. 2013;13:831–49.PubMedGoogle Scholar
  17. 17.
    Alonso-Magdalena P, Quesada I, Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol. 2011;7:346–53.PubMedGoogle Scholar
  18. 18.
    Lee DH, Steffes MW, Sjodin A, Jones RS, Needham LL, et al. Low dose of some persistent organic pollutants predicts type 2 diabetes: a nested case-control study. Environ Health Perspect. 2010;118:1235–42.PubMedCentralPubMedGoogle Scholar
  19. 19.
    De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health. 2012:713696.Google Scholar
  20. 20.
    Regnier SM, Sargis RM. Adipocytes under assault: environmental disruption of adipose physiology. Biochim Biophys Acta. 2013;1842(3):520–33Google Scholar
  21. 21.
    Sargis, RM. The Hijacking of Cellular Signaling and the Diabetes Epidemic: Mechanisms of Environmental Disruption of Insulin Action and Glucose Homeostasis. Diabetes & Metabolism Journal, 2014;38:13–24.Google Scholar
  22. 22.•
    Lind L, Lind PM. Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease? J Intern Med. 2012;271:537–53. An excellent review suggesting that environmental contaminants may play a role in cardiovascular disease. This review also discusses the sources of exposure to several chemicals linked to cardiovascular disease.PubMedGoogle Scholar
  23. 23.••
    Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiologic studies: a national toxicology program workshop review. Environ Health Perspect. 2013;121:774–83. A comprehensive review of the literature linking persistent organic pollutants with the development of diabetes. Based on this analysis, the authors concluded that there is sufficient evidence to suggest a link between persistent organic pollutants and diabetes.PubMedCentralPubMedGoogle Scholar
  24. 24.•
    Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, et al. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect. 2012;120:1658–70. A comprehensive review of the evidence linking arsenic to diabetes. Although the authors note that the connection is not firm, there is some evidence supporting a potential role for arsenic in the development of diabetes in certain populations.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs Jr DR, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012;33:378–455.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Lang IA, Galloway TS, Scarlett A. Association of urinary bisphenol a concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008;300:1303–10.PubMedGoogle Scholar
  27. 27.
    Gasull M, Pumarega J, Tellez-Plaza M, Castell C, Tresserras R, et al. Blood concentrations of persistent organic pollutants and prediabetes and diabetes in the general population of Catalonia. Environ Sci Technol. 2012;46:7799–810.PubMedGoogle Scholar
  28. 28.
    Hoogduijn MJ, Rakonczay Z, Genever PG. The effects of anticholinergic insecticides on human mesenchymal stem cells. Toxicol Sci. 2006;94:342–50.PubMedGoogle Scholar
  29. 29.
    Roos V, Rönn M, Salihovic S, Lind L, Bavel Bv, et al. Circulating levels of persistent organic pollutants in relation to visceral and subcutaneous adipose tissue by abdominal MRI. Obesity. 2013;21(2):413–8Google Scholar
  30. 30.
    Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. Mol Nutr Food Res. 2007;51:899–911.PubMedGoogle Scholar
  31. 31.
    Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect. 2007;115:876–82.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Kim JH, Park HY, Bae S, Lim YH, Hong YC. Diethylhexyl phthalates is associated with insulin resistance via oxidative stress in the elderly: a panel study. PLoS One. 2013;8:e71392.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Wang T, Li M, Chen B, Xu M, Xu Y, et al. Urinary Bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97:E223–7.PubMedGoogle Scholar
  34. 34.
    Chang JW, Chen HL, Su HJ, Liao PC, Guo HR, et al. Dioxin exposure and insulin resistance in Taiwanese living near a highly contaminated area. Epidemiology. 2010;21:56–61.PubMedGoogle Scholar
  35. 35.
    Brook RD, Xu X, Bard RL, Dvonch JT, Morishita M, et al. Reduced metabolic insulin sensitivity following sub-acute exposures to low levels of ambient fine particulate matter air pollution. Sci Total Environ. 2013;448:66–71.PubMedGoogle Scholar
  36. 36.
    Coogan PF, White LF, Jerrett M, Brook RD, Su JG, et al. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. Circulation. 2012;125:767–72.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Kim JH, Hong YC. GSTM1, GSTT1, and GSTP1 polymorphisms and associations between air pollutants and markers of insulin resistance in elderly Koreans. Environ Health Perspect. 2012;120:1378–84.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Greenberg CC, Danos AM, Brady MJ. Central role for protein targeting to glycogen in the maintenance of cellular glycogen stores in 3T3-L1 adipocytes. Mol Cell Biol. 2006;26:334–42.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Lind PM, Lind L. Circulating levels of bisphenol A and phthalates are related to carotid atherosclerosis in the elderly. Atherosclerosis. 2011;218:207–13.PubMedGoogle Scholar
  40. 40.
    Lind PM, van Bavel B, Salihovic S, Lind L. Circulating levels of persistent organic pollutants (POPs) and carotid atherosclerosis in the elderly. Environ Health Perspect. 2012;120:38–43.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Osorio-Yanez C, Ayllon-Vergara JC, Aguilar-Madrid G, Arreola-Mendoza L, Hernandez-Castellanos E, et al. Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environ Health Perspect. 2013;121:1090–6.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006;97:175–80.PubMedGoogle Scholar
  43. 43.
    Burgess JL, Kurzius-Spencer M, O'Rourke MK, Littau SR, Roberge J, et al. Environmental arsenic exposure and serum matrix metalloproteinase-9. J Expo Sci Environ Epidemiol. 2013;23:163–9.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Chen Y, Wu F, Graziano JH, Parvez F, Liu M, et al. Arsenic exposure from drinking water, arsenic methylation capacity, and carotid intima-media thickness in Bangladesh. Am J Epidemiol. 2013;178:372–81.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109:III15–9.PubMedGoogle Scholar
  46. 46.
    Everett CJ, Mainous III AG, Frithsen IL, Player MS, Matheson EM. Association of polychlorinated biphenyls with hypertension in the 1999-2002 National Health and Nutrition Examination Survey. Environ Res. 2008;108:94–7.PubMedGoogle Scholar
  47. 47.
    Bannenberg G, Martin HJ, Belai I, Maser E. 11beta-Hydroxysteroid dehydrogenase type 1: tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone. Chem Biol Interact. 2003;143–4:449–57.Google Scholar
  48. 48.
    Karim MR, Rahman M, Islam K, Mamun AA, Hossain S, et al. Increases in oxidized low-density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol Sci. 2013;135:17–25.PubMedGoogle Scholar
  49. 49.
    Auerbach O, Hammond EC, Garfinkel L. Smoking in relation to atherosclerosis of the coronary arteries. N Engl J Med. 1965;273:775–9.PubMedGoogle Scholar
  50. 50.
    Nazaroff WW, Singer BC. Inhalation of hazardous air pollutants from environmental tobacco smoke in US residences. J Expo Anal Environ Epidemiol. 2004;14 Suppl 1:S71–7.PubMedGoogle Scholar
  51. 51.
    Ding YS, Zhang L, Jain RB, Jain N, Wang RY, et al. Levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons in mainstream smoke from different tobacco varieties. Cancer Epidemiol Biomarkers Prev. 2008;17:3366–71.PubMedGoogle Scholar
  52. 52.
    Invernizzi G, Ruprecht A, Mazza R, Rossetti E, Sasco A, et al. Particulate matter from tobacco versus diesel car exhaust: an educational perspective. Tob Control. 2004;13:219–21.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Bae S, Pan XC, Kim SY, Park K, Kim YH, et al. Exposures to particulate matter and polycyclic aromatic hydrocarbons and oxidative stress in schoolchildren. Environ Health Perspect. 2010;118:579–83.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Pope III CA, Burnett RT, Thurston GD, Thun MJ, Calle EE, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiologic evidence of general pathophysiological pathways of disease. Circulation. 2004;109:71–7.PubMedGoogle Scholar
  55. 55.
    Fagerberg B, Bergstrom G, Boren J, Barregard L. Cadmium exposure is accompanied by increased prevalence and future growth of atherosclerotic plaques in 64-year-old women. J Intern Med. 2012;272:601–10.PubMedGoogle Scholar
  56. 56.
    Messner B, Knoflach M, Seubert A, Ritsch A, Pfaller K, et al. Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. Arterioscler Thromb Vasc Biol. 2009;29:1392–8.PubMedGoogle Scholar
  57. 57.
    Richardson VM, Staskal DF, Ross DG, Diliberto JJ, DeVito MJ, et al. Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. Toxicol Appl Pharmacol. 2008;226:244–50.PubMedGoogle Scholar
  58. 58.
    Baker NA, Karounos M, English V, Fang J, Wei Y, et al. Coplanar polychlorinated biphenyls impair glucose homeostasis in lean C57BL/6 mice and mitigate beneficial effects of weight loss on glucose homeostasis in obese mice. Environ Health Perspect. 2013;121:105–10.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Ogino K, Inukai T, Miura Y, Matsui H, Takemura Y. Triphenyltin chloride induces glucose intolerance by the suppression of insulin release from hamster pancreatic beta-cells. Exp Clin Endocrinol Diabetes. 1996;104:409–11.PubMedGoogle Scholar
  60. 60.
    Hill DS, Wlodarczyk BJ, Mitchell LE, Finnell RH. Arsenate-induced maternal glucose intolerance and neural tube defects in a mouse model. Toxicol Appl Pharmacol. 2009;239:29–36.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Gray SL, Shaw AC, Gagne AX, Chan HM. Chronic exposure to PCBs (Aroclor 1254) exacerbates obesity-induced insulin resistance and hyperinsulinemia in mice. J Toxicol Environ Health A. 2013;76:701–15.PubMedGoogle Scholar
  62. 62.•
    Alonso-Magdalena P, Vieira E, Soriano S, Menes L, Burks D, et al. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect. 2010;118:1243–50. An important manuscript from a productive group specifically linking developmental endocrine disruptor exposure to metabolic derangements.PubMedCentralPubMedGoogle Scholar
  63. 63.
    Liu J, Yu P, Qian W, Li Y, Zhao J, et al. Perinatal bisphenol A exposure and adult glucose homeostasis: identifying critical windows of exposure. PLoS One. 2013;8:e64143.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Nash JT, Szabo DT, Carey GB. Polybrominated diphenyl ethers alter hepatic phosphoenolpyruvate carboxykinase enzyme kinetics in male Wistar rats: implications for lipid and glucose metabolism. J Toxicol Environ Health A. 2013;76:142–56.Google Scholar
  65. 65.
    Ruzzin J, Petersen R, Meugnier E, Madsen L, Lock EJ, et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect. 2010;118:465–71.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Lim S, Ahn SY, Song IC, Chung MH, Jang HC, et al. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One. 2009;4:e5186.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Yan YH, Chou CC, Lee CT, Liu JY, Cheng TJ. Enhanced insulin resistance in diet-induced obese rats exposed to fine particles by instillation. Inhal Toxicol. 2011;23:507–19.PubMedGoogle Scholar
  68. 68.
    Paul DS, Walton FS, Saunders RJ, Stýblo M. Characterization of the impaired glucose homeostasis produced in C57BL/6 mice by chronic exposure to arsenic and high-fat diet. Environ Health Perspect. 2011;119:1104–9.PubMedCentralPubMedGoogle Scholar
  69. 69.
    McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85:571–633.PubMedGoogle Scholar
  70. 70.
    Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology. 2006;147:S11–7.PubMedGoogle Scholar
  71. 71.
    Manikkam M, Guerrero-Bosagna C, Tracey R, Haque MM, Skinner MK. Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures. PLoS One. 2012;7:e31901.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Angle BM, Do RP, Ponzi D, Stahlhut RW, Drury BE, et al. Metabolic disruption in male mice due to fetal exposure to low but not high doses of bisphenol A (BPA): evidence for effects on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. Reprod Toxicol. 2013;42:256–68.Google Scholar
  73. 73.
    Wei J, Lin Y, Li Y, Ying C, Chen J, et al. Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat diet. Endocrinology. 2011;152:3049–61.PubMedGoogle Scholar
  74. 74.
    Leibel RL. Molecular physiology of weight regulation in mice and humans. Int J Obes (Lond). 2008;32 Suppl 70:S98–108.Google Scholar
  75. 75.
    Lv Z, Li G, Li Y, Ying C, Chen J, et al. Glucose and lipid homeostasis in adult rat is impaired by early-life exposure to perfluorooctane sulfonate. Environ Toxicol. 2013;28:532–42.PubMedGoogle Scholar
  76. 76.
    White SS, Fenton SE, Hines EP. Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol. 2011;127:16–26.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706–21.PubMedGoogle Scholar
  78. 78.
    Dalton TP, Kerzee JK, Wang B, et al. Dioxin exposure is an environmental risk factor for ischemic heart disease. Cardiovasc Toxicol. 2001;01:285–98.Google Scholar
  79. 79.
    Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, et al. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol. 2011;31:1260–7.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Curfs DM, Knaapen AD, Pachen DM. Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB. 2005;19(10):1290–2.Google Scholar
  81. 81.
    Chen T, Jia G, Wei Y, Li J. Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice. Toxicol Lett. 2013;223:146–53.PubMedGoogle Scholar
  82. 82.
    Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341–55.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Rogalska J, Brzoska MM, Roszczenko A, Moniuszko-Jakoniuk J. Enhanced zinc consumption prevents cadmium-induced alterations in lipid metabolism in male rats. Chem Biol Interact. 2009;177:142–52.PubMedGoogle Scholar
  84. 84.
    Olisekodiaka MJ, Igbeneghu CA, Onuegbu AJ, Oduru R, Lawal AO. Lipid, lipoproteins, total antioxidant status and organ changes in rats administered high doses of cadmium chloride. Med Princ Pract. 2012;21:156–9.PubMedGoogle Scholar
  85. 85.
    Cheng TJ, Chuu JJ, Chang CY, Tsai WC, Chen KJ, et al. Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. Toxicol Appl Pharmacol. 2011;256:146–53.PubMedGoogle Scholar
  86. 86.
    Miyawaki J, Sakayama K, Kato H. Perinatal and postnatal exposure to bisphenol A increases adipose tissue mass and serum cholesterol level in mice. J Atheroscler Thromb. 2007;14(5):245–52.Google Scholar
  87. 87.
    Sugai E, Yoshioka W, Kakeyama M, Ohsako S, Tohyama C. In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin modulates dysregulation of the lipid metabolism in mouse offspring fed a high-calorie diet. J Appl Toxicol. 2013;34(3):296–306.Google Scholar
  88. 88.
    Bruin JE, Gerstein HC, Holloway AC. Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicol Sci. 2010;116:364–74.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Xiao D, Huang X, Yang S, Zhang L. Estrogen normalizes perinatal nicotine-induced hypertensive responses in adult female rat offspring. Hypertension. 2013;61:1246–54.PubMedCentralPubMedGoogle Scholar
  90. 90.
    Holloway AC, Cuu DQ, Morrison KM, Gerstein HC, Tarnopolsky MA. Transgenerational effects of fetal and neonatal exposure to nicotine. Endocrine. 2007;31:254–9.PubMedGoogle Scholar
  91. 91.
    Heeschen C, Jang JJ, Weis M. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833–9.PubMedGoogle Scholar
  92. 92.
    Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.PubMedGoogle Scholar
  93. 93.
    Kurita H, Yoshioka W, Nishimura N, Kubota N, Kadowaki T, et al. Aryl hydrocarbon receptor-mediated effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on glucose-stimulated insulin secretion in mice. J Appl Toxicol. 2009;29:689–94.PubMedGoogle Scholar
  94. 94.
    Piaggi S, Novelli M, Martino L, Masini M, Raggi C, et al. Cell death and impairment of glucose-stimulated insulin secretion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the beta-cell line INS-1E. Toxicol Appl Pharmacol. 2007;220:333–40.PubMedGoogle Scholar
  95. 95.
    Novelli M, Piaggi S, De Tata V. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-induced impairment of glucose-stimulated insulin secretion in isolated rat pancreatic islets. Toxicol Lett. 2005;156:307–14.PubMedGoogle Scholar
  96. 96.
    Wassermann D, Wassermann M, Lemesch C. Ultrastructure of beta-cells of the endocrine pancreas in rats receiving polychlorinated biphenyls. Environ Physiol Biochem. 1975;5:322–40.Google Scholar
  97. 97.
    Alonso-Magdalena P, Laribi O, Ropero AB, Fuentes E, Ripoll C, et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect. 2005;113:969–77.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Soriano S, Alonso-Magdalena P, Garcia-Arevalo M, Novials A, Muhammed SJ, et al. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor beta. PLoS One. 2012;7:e31109.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Miura Y, Matsui H. Triphenyltin impairs a protein kinase A (PKA)-dependent increase of cytosolic Na + and Ca2+ and PKA-independent increase of cytosolic Ca2+ associated with insulin secretion in hamster pancreatic beta-cells. Toxicol Appl Pharmacol. 2006;216:363–72.PubMedGoogle Scholar
  100. 100.
    Chang KC, Hsu CC, Liu SH, Su CC, Yen CC, et al. Cadmium induces apoptosis in pancreatic beta-cells through a mitochondria-dependent pathway: the role of oxidative stress-mediated c-Jun N-terminal kinase activation. PLoS One. 2013;8:e54374.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Chen YW, Huang CF, Yang CY, Yen CC, Tsai KS, et al. Inorganic mercury causes pancreatic beta-cell death via the oxidative stress-induced apoptotic and necrotic pathways. Toxicol Appl Pharmacol. 2010;243:323–31.PubMedGoogle Scholar
  102. 102.
    Douillet C, Currier J, Saunders J, Bodnar WM, Matousek T, et al. Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets. Toxicol Appl Pharmacol. 2013;267:11–5.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Fu J, Woods CG, Yehuda-Shnaidman E, Zhang Q, Wong V, et al. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect. 2010;118:864–70.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Fischer LJ, Zhou HR, Wagner MA. Polychlorinated biphenyls release insulin from RINm5F cells. Life Sci. 1996;59:2041–9.PubMedGoogle Scholar
  105. 105.
    Nishiumi S, Yoshida M, Azuma T, Yoshida K, Ashida H. 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs an insulin signaling pathway through the induction of tumor necrosis factor-alpha in adipocytes. Toxicol Sci. 2010;115:482–91.PubMedGoogle Scholar
  106. 106.
    Jayashree S, Indumathi D, Akilavalli N, Sathish S, Selvaraj J, et al. Effect of Bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino rat. Environ Toxicol Pharmacol. 2013;35:300–10.PubMedGoogle Scholar
  107. 107.
    Rajesh P, Sathish S, Srinivasan C, Selvaraj J, Balasubramanian K. Phthalate is associated with insulin resistance in adipose tissue of male rat: role of antioxidant vitamins. J Cell Biochem. 2013;114:558–69.PubMedGoogle Scholar
  108. 108.
    Sargis RM, Neel BA, Brock CO, Lin Y, Hickey AT, et al. The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1 levels. Biochim Biophys Acta. 1822;2012:952–60.Google Scholar
  109. 109.
    Zheng Z, Xu X, Zhang X, Wang A, Zhang C, et al. Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model. J Hepatol. 2013;58:148–54.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Xue P, Hou Y, Zhang Q, Woods CG, Yarborough K, et al. Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. Biochem Biophys Res Commun. 2011;407:360–5.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Sun Q, Yue P, Deiuliis JA, Lumeng CN, Kampfrath T, et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation. 2009;119:538–46.PubMedGoogle Scholar
  112. 112.
    Wang J, Lv X, Du Y. Inflammatory response and insulin signaling alteration induced by PCB77. J Environ Sci (China). 2010;22:1086–90.Google Scholar
  113. 113.
    Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS, et al. Arsenic inhibits myogenic differentiation and muscle regeneration. Environ Health Perspect. 2010;118:949–56.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Han JC, Park SY, Hah BG, Choi GH, Kim YK, et al. Cadmium induces impaired glucose tolerance in rat by down-regulating glucose transporter type 4 (GLUT4) expression in adipocytes. Arch Biochem Biophys. 2003;413:213–20.PubMedGoogle Scholar
  115. 115.
    Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55:2319–26.Google Scholar
  116. 116.
    Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, et al. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect. 2008;116:1642–7.PubMedCentralPubMedGoogle Scholar
  117. 117.
    Kawakami T, Sugimoto H, Furuichi R, Kadota Y, Inoue M, et al. Cadmium reduces adipocyte size and expression levels of adiponectin and Peg1/Mest in adipose tissue. Toxicology. 2010;267:20–6.PubMedGoogle Scholar
  118. 118.
    Zuo Z, Chen S, Wu T, Zhang J, Su Y, et al. Tributyltin causes obesity and hepatic steatosis in male mice. Environ Toxicol. 2011;26:79–85.Google Scholar
  119. 119.
    Xu Z, Xu X, Zhong M, Hotchkiss IP, Lewandowski RP, et al. Ambient particulate air pollution induces oxidative stress and alterations of mitochondria and gene expression in brown and white adipose tissues. Part Fibre Toxicol. 2011;8:20.PubMedCentralPubMedGoogle Scholar
  120. 120.
    Wang M, Wang D, Zhang Y, Wang X, Liu Y, et al. Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;229:62–70.PubMedGoogle Scholar
  121. 121.
    Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79:360–76.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Majkova Z, Layne J, Sunkara M, Morris AJ, Toborek M, et al. Omega-3 fatty acid oxidation products prevent vascular endothelial cell activation by coplanar polychlorinated biphenyls. Toxicol Appl Pharmacol. 2011;251:41–9.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Vogel CFA, Sciullo E, Wong P, Kuzmicky P, Kado N, et al. Induction of proinflammatory cytokines and C-reactive protein in human macrophage cell line U937 exposed to air pollution particulates. Environ Health Perspect. 2005;113:1536–41.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Libby P. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.PubMedGoogle Scholar
  125. 125.
    Majkova Z, Smart E, Toborek M, Hennig B. Upregulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent. Toxicol Appl Pharmacol. 2009;237:1–7.PubMedCentralPubMedGoogle Scholar
  126. 126.
    Knaapen AM, Curfs DM, Pachen DM, Gottschalk RW, de Winther MP, et al. The environmental carcinogen benzo[a]pyrene induces expression of monocyte-chemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. Mutat Res. 2007;621:31–41.PubMedGoogle Scholar
  127. 127.
    Vogel CF, Nishimura N, Sciullo E, Wong P, Li W, et al. Modulation of the chemokines KC and MCP-1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice. Arch Biochem Biophys. 2007;461:169–75.PubMedGoogle Scholar
  128. 128.
    Arsenescu V, Arsenescu RI, King V, Swanson H, Cassis LA. Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Environ Health Perspect. 2008;116:761–8.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Angeli JK, Cruz Pereira CA, de Oliveira FT, Stefanon I, Padilha AS, et al. Cadmium exposure induces vascular injury due to endothelial oxidative stress: the role of local angiotensin II and COX-2. Free Radic Biol Med. 2013;65C:838–48.Google Scholar
  130. 130.
    Hennig B. Proinflammatory properties of coplanar PCBs: in vitro and in vivo evidence. Toxicol Appl Pharmacol. 2002;181:174–83.PubMedGoogle Scholar
  131. 131.
    Birch LL, Deysher M. Caloric compensation and sensory specific satiety: evidence for self-regulation of food intake by young children. Appetite. 1986;7:323–31.PubMedGoogle Scholar
  132. 132.
    Arsenescu V, Arsenescu R, Parulkar M, Karounos M, Zhang X, et al. Polychlorinated biphenyl 77 augments angiotensin II-induced atherosclerosis and abdominal aortic aneurysms in male apolipoprotein E deficient mice. Toxicol Appl Pharmacol. 2011;257:148–54.PubMedCentralPubMedGoogle Scholar
  133. 133.
    Fang CC, Chen FY, Chen CR, Liu CC, Wong LC, et al. Cyprodinil as an activator of aryl hydrocarbon receptor. Toxicology. 2013;304:32–40.PubMedGoogle Scholar
  134. 134.
    Druwe IL, Sollome JJ, Sanchez-Soria P, Hardwick RN, Camenisch TD, et al. Arsenite activates NFkappaB through induction of C-reactive protein. Toxicol Appl Pharmacol. 2012;261:263–70.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol. 2000;20:1430–42.PubMedGoogle Scholar
  136. 136.
    Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive oxygen species (ROS): potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal. 2013;19:1085–94.PubMedCentralPubMedGoogle Scholar
  137. 137.
    Ceriello A. Evidence for an Independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211–8.PubMedGoogle Scholar
  138. 138.
    Hossain E, Ota A, Karnan S, Damdindorj L, Takahashi M, et al. Arsenic augments the uptake of oxidized LDL by upregulating the expression of lectin-like oxidized LDL receptor in mouse aortic endothelial cells. Toxicol Appl Pharmacol. 2013;273(3):651–8.Google Scholar
  139. 139.
    Xiao D, Huang X, Lawrence J, Yang S, Zhang L. Fetal and neonatal nicotine exposure differentially regulates vascular contractility in adult male and female offspring. J Pharmacol Exp Ther. 2007;320:654–61.PubMedGoogle Scholar
  140. 140.
    Tavolari S, Bucci L, Tomasi V, Guarnieri T. Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis. Toxicology. 2006;218:67–74.PubMedGoogle Scholar
  141. 141.
    Ribeiro-Varandas E, Viegas W, Sofia Pereira H, Delgado M. Bisphenol A at concentrations found in human serum induces aneugenic effects in endothelial cells. Mutat Res. 2013;751:27–33.PubMedGoogle Scholar
  142. 142.
    Adigun AA, Wrench N, Seidler FJ, Slotkin TA. Neonatal organophosphorus pesticide exposure alters the developmental trajectory of cell-signaling cascades controlling metabolism: differential effects of diazinon and parathion. Environ Health Perspect. 2010;118:210–5.PubMedCentralPubMedGoogle Scholar
  143. 143.
    Kucka M, Pogrmic-Majkic K, Fa S, Stojilkovic SS, Kovacevic R. Atrazine acts as an endocrine disrupter by inhibiting cAMP-specific phosphodiesterase-4. Toxicol Appl Pharmacol. 2012;265:19–26.PubMedCentralPubMedGoogle Scholar
  144. 144.
    Atanasov AG, Tam S, Röcken JM, Baker ME, Odermatt A. Inhibition of 11β-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. Biochem Biophys Res Commun. 2003;308:257–62.PubMedGoogle Scholar
  145. 145.
    Atanasov AG, Nashev LG, Tam S, Baker ME, Odermatt A. Organotins disrupt the 11β-Hydroxysteroid Dehydrogenase Type 2–dependent local inactivation of glucocorticoids. Environ Health Perspect. 2005;113:1600–6.PubMedCentralPubMedGoogle Scholar
  146. 146.
    Yang K, Julan L, Rubio F, Sharma A, Guan H. Cadmium reduces 11 beta-hydroxysteroid dehydrogenase type 2 activity and expression in human placental trophoblast cells. Am J Physiol Endocrinol Metab. 2006;290:E135–42.PubMedGoogle Scholar
  147. 147.
    Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell Endocrinol. 2009;304:84–9.PubMedCentralPubMedGoogle Scholar
  148. 148.
    Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol. 2011;24:6–19.PubMedCentralPubMedGoogle Scholar
  149. 149.
    Joharapurkar AA, Dhote VV, Jain MR. Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia. J Med Chem. 2012;55:5649–75.PubMedGoogle Scholar
  150. 150.
    Kitamura S, Jinno N, Suzuki T, Sugihara K, Ohta S, et al. Thyroid hormone-like and estrogenic activity of hydroxylated PCBs in cell culture. Toxicology. 2005;208:377–87.PubMedGoogle Scholar
  151. 151.
    Mastorakos G, Karoutsou EI, Mizamtsidi M, Creatsas G. The menace of endocrine disruptors on thyroid hormone physiology and their impact on intrauterine development. Endocrine. 2007;31:219–37.PubMedGoogle Scholar
  152. 152.
    Neel BA, Brady MJ, Sargis RM. The endocrine disrupting chemical tolylfluanid alters adipocyte metabolism via glucocorticoid receptor activation. Mol Endocrinol. 2013;27:394–406.PubMedCentralPubMedGoogle Scholar
  153. 153.
    Bodwell JE, Kingsley LA. Arsenic at very low concentrations alters glucocorticoid receptor (GR)-mediated gene activation but not GR-mediated gene repression: complex dose-response effects are closely correlated with levels of activated GR and require a functional GR DNA binding domain. Chem Res Toxicol. 2004;17:1064–76.PubMedGoogle Scholar
  154. 154.
    Zhou T, Cong S, Sun S, Sun H, Zou R, et al. Identification of endocrine disrupting chemicals activating SXR-mediated transactivation of CYP3A and CYP7A1. Mol Cell Endocrinol. 2013;365:36–43.PubMedGoogle Scholar
  155. 155.
    Sargis RM, Subbaiah PV. Trans Unsaturated Fatty Acids are Less Oxidizable than Cis Unsaturated Fatty Acids and Protect Endogenous Lipids from Oxidation in Lipoproteins and Lipid Bilayers. Biochemistry. 2003;42:11533–43.Google Scholar
  156. 156.
    Sargis RM, Subbaiah PV. Protection of membrane cholesterol by sphingomyelin against free radical-mediated oxidation. Free Radic Biol Med. 2006;40:2092–102.PubMedCentralPubMedGoogle Scholar
  157. 157.
    Ratajczak MK, Ko YT, Lange Y, Steck TL, Lee KY. Cholesterol displacement from membrane phospholipids by hexadecanol. Biophys J. 2007;93:2038–47.PubMedCentralPubMedGoogle Scholar
  158. 158.
    Chen S, Subbaiah PV. Regioisomers of phosphatidylcholine containing DHA and their potential to deliver DHA to the brain: role of phospholipase specificities. Lipids. 2013;48:675–86.PubMedGoogle Scholar
  159. 159.
    Marmugi A, Ducheix S, Lasserre F, Polizzi A, Paris A, et al. Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. Hepatology. 2012;55:395–407.PubMedGoogle Scholar
  160. 160.
    Beausoleil C, Ormsby JN, Gies A, Hass U, Heindel JJ, et al. Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary. Chemosphere. 2013;93:847–56.PubMedGoogle Scholar
  161. 161.
    Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol. 2005;231:75–85.PubMedGoogle Scholar
  162. 162.
    Ma Y, Xia W, Wang DQ, Wan YJ, Xu B, et al. Hepatic DNA methylation modifications in early development of rats resulting from perinatal BPA exposure contribute to insulin resistance in adulthood. Diabetologia. 2013;56:2059–67.PubMedGoogle Scholar
  163. 163.
    Han JC, Park SY, Hah BG, Choi GH, Kim YK, et al. Cadmium induces impaired glucose tolerance in rat by down-regulating GLUT4 expression in adipocytes. Arch Biochem Biophys. 2003;413:213–20.PubMedGoogle Scholar
  164. 164.
    Seilkop SK, Campen MJ, Lund AK, McDonald JD, Mauderly JL. Identification of chemical components of combustion emissions that affect pro-atherosclerotic vascular responses in mice. Inhal Toxicol. 2012;24:270–87.PubMedCentralPubMedGoogle Scholar
  165. 165.
    Dalton TP, Kerzee JK, Wang B. Dioxin exposure is an environmental risk factor for ischemic heart disease. Cardiovasc Toxicol. 2001;01:285–98.Google Scholar
  166. 166.
    Kopf PG, Huwe JK, Walker MK. Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide. Cardiovasc Toxicol. 2008;8:181–93.PubMedCentralPubMedGoogle Scholar
  167. 167.
    Panahi P, Vosough-Ghanbari S, Pournourmohammadi S, Ostad SN, Nikfar S, et al. Stimulatory effects of malathion on the key enzymes activities of insulin secretion in langerhans islets, glutamate dehydrogenase and glucokinase. Toxicol Mech Methods. 2006;16:161–7.PubMedGoogle Scholar
  168. 168.
    Lind PM, Orberg J, Edlund UB, Sjoblom L, Lind L. The dioxin-like pollutant PCB 126 (3,3',4,4',5-pentachlorobiphenyl) affects risk factors for cardiovascular disease in female rats. Toxicol Lett. 2004;150:293–9.PubMedGoogle Scholar
  169. 169.
    Kampfrath T, Maiseyeu A, Ying Z, Shah Z, Deiuliis JA, et al. Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways. Circ Res. 2011;108:716–26.PubMedCentralPubMedGoogle Scholar
  170. 170.
    Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol. 2006;20:2141–55.PubMedGoogle Scholar
  171. 171.
    Zuo Z, Chen S, Wu T, Zhang J, Su Y, et al. Tributyltin causes obesity and hepatic steatosis in male mice. Environ Toxicol. 2011;26:79–85.PubMedGoogle Scholar
  172. 172.
    Li X, Pham HT, Janesick AS, Blumberg B. Triflumizole is an obesogen in mice that acts through peroxisome proliferator activated receptor gamma (PPARgamma). Environ Health Perspect. 2012;120:1720–6.PubMedCentralPubMedGoogle Scholar
  173. 173.
    Alves MG, Neuhaus-Oliveira A, Moreira PI, Socorro S, Oliveira PF. Exposure to 2,4-dichlorophenoxyacetic acid alters glucose metabolism in immature rat Sertoli cells. Reprod Toxicol. 2013;38:81–8.PubMedGoogle Scholar
  174. 174.
    Wens B, De Boever P, Verbeke M, Hollanders K, Schoeters G. Cultured human peripheral blood mononuclear cells alter their gene expression when challenged with endocrine-disrupting chemicals. Toxicology. 2013;303:17–24.PubMedGoogle Scholar
  175. 175.
    Wang Y, Hu H, Zhao M, Zhao J, Yin D, et al. Nonylphenol disrupts the cardio-protective effects of 17beta-estradiol on ischemia/reperfusion injury in isolated hearts of guinea pig. J Toxicol Sci. 2013;38:731–40.PubMedGoogle Scholar
  176. 176.
    Wang X, Porter W, Krishnan V, Narasimhan TR, Safe S. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol Cell Endocrinol. 1993;96:159–66.PubMedGoogle Scholar
  177. 177.
    Puga A, Sartor MA, Huang MY, Kerzee JK, Wei YD, et al. Gene expression profiles of mouse aorta and cultured vascular smooth muscle cells differ widely, yet show common responses to dioxin exposure. Cardiovasc Toxicol. 2004;4:385–404.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Committee on Molecular Pathogenesis and Molecular MedicineUniversity of ChicagoChicagoUSA
  2. 2.Committee on Molecular Metabolism and Nutrition, Kovler Diabetes Center, Section of Endocrinology, Diabetes and MetabolismUniversity of ChicagoChicagoUSA

Personalised recommendations